Skip to main content
Top
Published in: Clinical and Experimental Medicine 1/2024

Open Access 01-12-2024 | Vasculitis | Research

Clinical features and prognosis of ANCA-associated vasculitis patients who were double-seropositive for myeloperoxidase-ANCA and proteinase 3-ANCA

Authors: Yizi Gong, Chanjuan Shen, Ting Meng, Wei Lin, Xueling Hu, Rong Tang, Qi Xiong, Joshua D. Ooi, Peter J. Eggenhuizen, Jinbiao Chen, Ya-Ou Zhou, Hui Luo, Jia Xu, Ning Liu, Ping Xiao, Xiangcheng Xiao, Yong Zhong

Published in: Clinical and Experimental Medicine | Issue 1/2024

Login to get access

Abstract

Anti-neutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) patients with dual positivity for proteinase 3-ANCA (PR3-ANCA) and myeloperoxidase-ANCA (MPO-ANCA) are uncommon. We aimed to investigate these idiopathic double-positive AAV patients’ clinical features, histological characteristics, and prognosis. We reviewed all the electronic medical records of patients diagnosed with AAV to obtain clinical data and renal histological information from January 2010 to December 2020 in a large center in China. Patients were assigned to the MPO-AAV group or PR3-AAV group or idiopathic double-positive AAV group by ANCA specificity. We explored features of idiopathic double-positive AAV. Of the 340 patients who fulfilled the study inclusion criteria, 159 (46.76%) were female, with a mean age of 58.41 years at the time of AAV diagnosis. Similar to MPO-AAV, idiopathic double-positive AAV patients were older and had more severe anemia, lower Birmingham Vasculitis Activity Score (BVAS) and C-reactive protein (CRP) levels, less ear, nose, and throat (ENT) involvement, higher initial serum creatinine and a lower estimated glomerular filtration rate (eGFR) when compared with PR3-AAV (P < 0.05). The proportion of normal glomeruli of idiopathic double-positive AAV was the lowest among the three groups (P < 0.05). The idiopathic double-positive AAV patients had the worst remission rate (58.8%) among the three groups (P < 0.05). The relapse rate of double-positive AAV (40.0%) was comparable with PR3-AAV (44.8%) (P > 0.05). Although there was a trend toward a higher relapse rate of idiopathic double-positive AAV (40.0%) compared with MPO-AAV (23.5%), this did not reach statistical significance (P > 0.05). The proportion of patients who progressed to ESRD was 47.1% and 44.4% in the idiopathic double-positive AAV group and MPO-AAV group respectively, without statistical significance. Long-term patient survival also varied among the three groups (P < 0.05). Idiopathic double-positive AAV is a rare clinical entity with hybrid features of MPO-AAV and PR3-AAV. MPO-AAV is the “dominant” phenotype in idiopathic double-positive AAV.
Literature
11.
go back to reference Suppiah R, Robson J, Grayson P, Ponte C, Craven A, Khalid S, et al. 2022 American college of rheumatology/European alliance of associations for rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis. 2022;81(3):321–6 (PubMed PMID: 35110332).CrossRefPubMed Suppiah R, Robson J, Grayson P, Ponte C, Craven A, Khalid S, et al. 2022 American college of rheumatology/European alliance of associations for rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis. 2022;81(3):321–6 (PubMed PMID: 35110332).CrossRefPubMed
12.
go back to reference Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222–7 (PubMed PMID: 16901958).CrossRefPubMed Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, Koldingsnes W, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007;66(2):222–7 (PubMed PMID: 16901958).CrossRefPubMed
14.
go back to reference Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7(1):33–9 (PubMed PMID: 8808107).CrossRefPubMed Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7(1):33–9 (PubMed PMID: 8808107).CrossRefPubMed
15.
go back to reference Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7(1):23–32 (PubMed PMID: 8808106).CrossRefPubMed Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7(1):23–32 (PubMed PMID: 8808106).CrossRefPubMed
24.
go back to reference Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66(5):605–17 (PubMed PMID: 17170053).CrossRefPubMed Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66(5):605–17 (PubMed PMID: 17170053).CrossRefPubMed
25.
go back to reference Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12 (PubMed PMID: 19414839).CrossRefPubMedPubMedCentral Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12 (PubMed PMID: 19414839).CrossRefPubMedPubMedCentral
28.
go back to reference Chou J, Randall K, Gatenby P. Clinical outcomes of patients with dual positivity for proteinase 3 and myeloperoxidase specific antineutrophil cytoplasmic antibodies. Int Med J. 2014;44:7 (PubMed PMID: WOS:000342722800020). Chou J, Randall K, Gatenby P. Clinical outcomes of patients with dual positivity for proteinase 3 and myeloperoxidase specific antineutrophil cytoplasmic antibodies. Int Med J. 2014;44:7 (PubMed PMID: WOS:000342722800020).
34.
go back to reference Haroun MK, Stone JH, Nair R, Racusen L, Hellmann DB, Eustace JA. Correlation of percentage of normal glomeruli with renal outcome in Wegener’s granulomatosis. Am J Nephrol. 2002;22(5–6):497–503 (PubMed PMID: 12381950).CrossRefPubMed Haroun MK, Stone JH, Nair R, Racusen L, Hellmann DB, Eustace JA. Correlation of percentage of normal glomeruli with renal outcome in Wegener’s granulomatosis. Am J Nephrol. 2002;22(5–6):497–503 (PubMed PMID: 12381950).CrossRefPubMed
42.
43.
go back to reference Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990;87(11):4115–9 (PubMed PMID: 2161532; PubMed Central PMCID: PMCQ1).CrossRefPubMedPubMedCentral Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A. 1990;87(11):4115–9 (PubMed PMID: 2161532; PubMed Central PMCID: PMCQ1).CrossRefPubMedPubMedCentral
44.
go back to reference Franssen CF, Huitema MG, Muller Kobold AC, Oost-Kort WW, Limburg PC, Tiebosch A, et al. In vitro neutrophil activation by antibodies to proteinase 3 and myeloperoxidase from patients with crescentic glomerulonephritis. J Am Soc Nephrol. 1999;10(7):1506–15 (PubMed PMID: 10405206; PubMed Central PMCID: PMCQ1).CrossRefPubMed Franssen CF, Huitema MG, Muller Kobold AC, Oost-Kort WW, Limburg PC, Tiebosch A, et al. In vitro neutrophil activation by antibodies to proteinase 3 and myeloperoxidase from patients with crescentic glomerulonephritis. J Am Soc Nephrol. 1999;10(7):1506–15 (PubMed PMID: 10405206; PubMed Central PMCID: PMCQ1).CrossRefPubMed
45.
go back to reference Espy C, Morelle W, Kavian N, Grange P, Goulvestre C, Viallon V, et al. Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener’s). Arthritis Rheum. 2011;63(7):2105–15. https://doi.org/10.1002/art.30362. (PubMed PMID: 21437874).CrossRefPubMed Espy C, Morelle W, Kavian N, Grange P, Goulvestre C, Viallon V, et al. Sialylation levels of anti-proteinase 3 antibodies are associated with the activity of granulomatosis with polyangiitis (Wegener’s). Arthritis Rheum. 2011;63(7):2105–15. https://​doi.​org/​10.​1002/​art.​30362. (PubMed PMID: 21437874).CrossRefPubMed
Metadata
Title
Clinical features and prognosis of ANCA-associated vasculitis patients who were double-seropositive for myeloperoxidase-ANCA and proteinase 3-ANCA
Authors
Yizi Gong
Chanjuan Shen
Ting Meng
Wei Lin
Xueling Hu
Rong Tang
Qi Xiong
Joshua D. Ooi
Peter J. Eggenhuizen
Jinbiao Chen
Ya-Ou Zhou
Hui Luo
Jia Xu
Ning Liu
Ping Xiao
Xiangcheng Xiao
Yong Zhong
Publication date
01-12-2024
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 1/2024
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-024-01318-y

Other articles of this Issue 1/2024

Clinical and Experimental Medicine 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.